Company Update (NASDAQ:CYTX): Cytori Therapeutics Inc Cell Therapy Leads to Improved Function and Reduced Scar Tissue in a Urinary Injury Model

Cytori Therapeutics Inc (NASDAQ:CYTX) announced the publication in The Journal of Urology of a preclinical study applying Adipose-Derived Regenerative Cells (ADRCs) prepared using Cytori Cell Therapy in a large animal model of urethral injury.

The results show that delivery of the cell therapy product immediately after injury resulted in a >50% decrease in fibrotic scar tissue from 17% of total urethral surface area in the control to 7% in the treated group (p=0.05) 30 days following treatment. The study further reported that delaying delivery of the cell therapy product until 30 days after injury—a time at which urethral fibrosis was well-established—led to >10-fold decrease in injured surface area (from 13% of the urethra in the control group to 1% in the treated group; p<0.05) at 60 days after injury (30 days after treatment). ADRC-treatment was also associated with a statistically significant increase in the maximum pressure generated by the urethra, an important component of urinary sphincter function.

This study was led by Drs. Giles Karsenty and Romain Boissier of Aix-Marseille University in Marseille, France supported by the team of Pr. Florence Sabatier of the Cell Therapy Department of Hôpital de le Conception, Assistance Publique-Hôpitaux de Marseille.

“These now published findings support the use of either immediate or delayed application of Cytori Cell Therapy to help reduce injury and scarring,” said Dr. Marc Hedrick, President and CEO of Cytori. “This important safety and proof of concept preclinical study will be useful in forthcoming regulatory submissions in the US, Europe and Japan.”

Data from this preclinical study supported the company’s recently enrolled the STAR clinical trial, anFDA-approved, 88 patient, multi-center, randomized controlled Phase III trial of Cytori Cell Therapy for the treatment of hand dysfunction and Raynaud’s Phenomenon in patients with scleroderma as well as the investigator-initiated, ADRESU urinary incontinence trial currently enrolling in Japan. A reduction in cutaneous fibrosis as measured by the modified Rodnan Skin Score (mRSS) of the hand was also noted in the previous published SCLERADEC I clinical trial. (Original Source)

Shares of Cytori are up nearly 2% to $2.33 in pre-market trading. CYTX has a 1-year high of $10.50 and a 1-year low of $1.92. The stock’s 50-day moving average is $3.42 and its 200-day moving average is $3.28.

On the ratings front, CYTX has been the subject of a number of recent research reports. In a report issued on March 28, Maxim Group analyst Jason Kolbert reiterated a Buy rating on CYTX, with a price target of $75, which implies an upside of 3189.5% from current levels. Separately, on March 24, Roth Capital’s Joseph Pantginis maintained a Buy rating on the stock and has a price target of $22.50.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Joseph Pantginis have a total average return of -14.9% and 9.8% respectively. Kolbert has a success rate of 30.4% and is ranked #3902 out of 3903 analysts, while Pantginis has a success rate of 39.2% and is ranked #170.

Cytori Therapeutics, Inc. is a late stage cell therapy company. Its develops autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. 


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts